Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biodegradable and non-biodegradable ocular implants have been used in several drug treatments for conditions such as diabetic macular edema and posterior uveitis, among others, and provide a method for sustained release of poorly soluble steroids.118,126”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [126]
Experimental — accuracy not yet measuredIn the citing paper
“In the field of ophthalmology, different routes of administration, such as subconjunctival, intravitreal, suprachoroidal and subretinal injections, are commonly used to treat various diseases61.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Hyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822 · cited 2×
“Micelles are nanosized amphiphilic core-shell (hydrophobic core, hydrophilic shell) carriers with polymeric surfactants [91,92].”
BackgroundPolymer nanoparticles: Preparation techniques and size-control parameters
Rao, J. P., & Geckeler, K. E. (2011) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.01.001 · Cited by 1,725 · cited 2×
“observed significant suppression of neovascularization [98].”
MethodDendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158 · cited 1×
“Dendrimers are synthetic three-dimensional repeating-unit branched macromolecules; polyamidoamine (PAMAM) and DAB polypropyleneimine (PPI/DAB) are widely used dendrimers for biomedical purposes [79,80].”
BackgroundRanibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
Hydrogels for Protein Delivery
Vermonden, T., Censi, R., & Hennink, W. E. (2012) · Chemical Reviews · doi:10.1021/cr200157d · Cited by 1,091
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Cited by
Items 101–200 of 213
Latest trends & strategies in ocular drug delivery
Kulkarni, N. S., Josowitz, A. D., James, R., Liu, Y., Rayaprolu, B. M., Sagdullaev, B. T., Bhalla, A. S., & Shameem, M. (2025) · Methods · doi:10.1016/j.ymeth.2025.02.003 · Cited by 8
Cammalleri, M., Filippi, L., Monte, M. D., & Bagnoli, P. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1408605 · Cited by 6
Yao, Y., Lei, X., Li, X., Ge, Y., Wang, Y., Qin, X., Gao, Y., Zhang, G., Lin, Y., Gao, S., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159618 · Cited by 7
Garcia-O’Farrill, N., Brown, G. T., & Hunter, A. A. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-02943-z · Cited by 6
“Subconjunctival injections provide a higher permeability through the retina and choroidal area than the topical route and are less invasive than intravitreal ones [15, 16].”
BackgroundGarrido, Á. S., Durán‐Lobato, M., Mate, A., Martín‐Banderas, L., & Vázquez, C. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123602 · Cited by 6
Lu, H., He, N., Zhang, L., You, Y., & Lv, Z. (2025) · Clinical ophthalmology · doi:10.2147/opth.s503273 · Cited by 6
“30 However, this method needs to be repeated, which increases the risk of infection and retinal detachment, as well as the inconvenience of frequent injections, which affects compliance.”
Diress, M., Ionescu, C. M., Foster, T., Lim, P., Sen, L. Y., Kovačević, B., Wagle, S. R., Mooranian, A., & Al‐Salami, H. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107172 · Cited by 5
Alshahrouri, B., Blass, B. E., Dürig, T., & Fassihi, R. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01253-8 · Cited by 5
“As a result, thermoresponsive hydrogels have been extensively investigated to extend the therapeutic duration of intravitreal medications (84, 85).”
Potential of TAK-593 Ophthalmic Emulsion for the Treatment of Age-Related Macular Degeneration
Mori, Y., Yamamoto, A., Nakagawa, A., Hikima, T., & Isowaki, A. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00066 · Cited by 5
Hiller, J. K., Sandås, E. M., Rootwelt, H., Vassli, A. Ø., Utheim, T. P., Moe, M. C., Elgstøen, K. B. P., & Petrovski, G. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0159 · Cited by 5
Askari, V. R., Rahimi, V. B., Tayebi-Khorrami, V., Fadaei, M. R., & Fadaei, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96116-5.00009-0 · Cited by 7
An update on the latest strategies in retinal drug delivery
Ranch, K. M., Chawnani, D., Jani, H., Acharya, D., Patel, C. A., Jacob, S., Babu, R. J., Tiwari, A. K., Al-Tabakha, M. M., & Boddu, S. H. S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2358886 · Cited by 5
“While some excellent reviews high-lighted drug delivery to the retina, they failed to discuss all aspects of small molecules and antibody-based drugs in a comprehensive manner [7–10].”
BackgroundPecorini, G., Votta, A., Tiralongo, G., Volpi, D., Ferraro, E., & Puppi, D. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105895 · Cited by 6
Recent progress in polymeric micelle-Enabled targeted Nanotherapeutics for diabetic retinopathy
Sil, D., Kumar, D., Kurmi, B. D., & Kumar, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106448 · Cited by 6
Nanoparticle-Based gene therapy strategies in retinal delivery
Foster, T., Lim, P., Wagle, S. R., Ionescu, C. M., Kovačević, B., McLenachan, S., Carvalho, L. S., Brunet, A. A., Mooranian, A., & Al‐Salami, H. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2024.2433563 · Cited by 6
“…administration. these are subretinal, sub-conjunctival, suprachoroidal, topical, and intravitreal, with each route having its pros and cons. to improve efficacy, a number of delivery systems are also used, including implants, dendrimers, liposomes, polymers, hydrogels, and combined systems [55].”
Kang, N., Jung, J. S., Hwang, J., Park, S.-E., Kwon, M., Yoon, H., Yong, J., Woo, H., & Park, K. (2024) · Biomedicines · doi:10.3390/biomedicines12020383 · Cited by 5
“Intravitreal injection has the advantage of delivering drugs directly to the vitreous and retina, but the technique is invasive with risks of increased intraocular pressure, infection, inflammation, potential damage to the lens, retinal toxicity, and detachment [62,63].”
BackgroundRossi, S., Gesualdo, C., Marano, E., Perrotta, R., Trotta, M. C., Giudice, A. D., & Simonelli, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1467160 · Cited by 6
Retinal safety and toxicity study of artesunate in vitro and in vivo
Lu, B.-W., Liang, Y., Liu, J., Sun, Z., So, K., & Chiu, K. (2022) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2022.11.003 · Cited by 4
“10 To investigate the safety of an intravitreal injection of ART, different doses (25, 50, 100 μ M, and 1 mM) were administrated to the mouse eyes.”
MethodTega, Y., Takeuchi, T., Nagano, M., Makino, R., Kubo, Y., Akanuma, S., & Hosoya, K. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100510 · Cited by 5
Can (Natural) deep eutectic systems increase the efficacy of ocular therapeutics?
Sarmento, C., Duarte, A. R. C., & Duarte, A. R. C. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114276 · Cited by 4
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
“65 Considered a safer alternative to viral vectors, nanocarriers have shown advantages that go beyond those of traditional viral vectors and have already made significant progress in the field of fundus disease therapy.”
BackgroundKumar, S., Cook, N. J., Gum, G. G., & Naageshwaran, V. (2021) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.01.03 · Cited by 4
A Bifunctional Peptide with Penetration Ability for Treating Retinal Angiogenesis via Eye Drops
Liao, J., Zhao, L., Chen, H., Zhao, C., Chen, S., Guo, X., Wang, F., Liu, X., & Zhang, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00683 · Cited by 4
Decoding Retinal Degeneration Diseases: From Molecular Pathways to Cutting-edge Therapies
Zhuang, Y., Lü, J., Li, J., Chen, C., & Liu, X. (2025) · Nature Cell and Science · doi:10.61474/ncs.2025.00021 · Cited by 3
Xu, J., Cai, T., Li, J., Ge‐Zhang, S., Jiang, Z., & Cao, M. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100477 · Cited by 4
“…patient outcomes, they are associated with significant challenges, including short intraocular drug residence times necessitating repeated injections (typically monthly or bimonthly), which places a substantial burden on patients and healthcare systems (Kim and Woo, 2021; Tabano et al., 2025).”
Intraocular drug delivery systems for Diabetic retinopathy: Current and future prospective
Taheri, S. L., Poorirani, S., & Mostafavi, S. A. (2024) · Bioimpacts · doi:10.34172/bi.30127 · Cited by 7
NOVEL APPROACHES IN OCULAR DRUG DELIVERY-A REVOLUTION
Kaushik, A., Mazumder, R., Padhi, S., Mazumder, A., BUDHORI, R., MANORMA, & Paul, S. D. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022v14i3.44045 · Cited by 5
Zhou, T., Li, X., Yang, J., Xia, H., Liu, Q., He, J., & Zhang, J. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0146 · Cited by 3
Esteruelas, G., Ortiz, A., Prat, J., Vega, E., Muñoz-Juncosa, M. M., García, M. L., Ettcheto, M., Camins, A., Sánchez‐López, E., & Pujol, M. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113394 · Cited by 3
Guo, Q., Li, Z., & Cao, F. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03305-z · Cited by 3
Borkenstein, A. F. M., Borkenstein, E.-M., & Presser, A. (2024) · Cureus · doi:10.7759/cureus.65888 · Cited by 3
Stančiauskaitė, M., Marksa, M., Іванаускас, Л., & Ramanauskienė, K. (2022) · Antioxidants · doi:10.3390/antiox11091771 · Cited by 6
Nanovesicular ultra-deformable transferosomes and transgelosomes for ocular drug delivery
Mohapatra, D., & Corson, T. W. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2510197 · Cited by 4
Yetisgin, A. A., Kutlu, Ö., & Çetinel, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107156 · Cited by 2
Revolutionizing Diabetic Macular Edema Treatment: FDA Approval of Susvimo
Kumar, D., Gupta, V., Tanwar, R., & Jaiswal, N. K. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01971-8 · Cited by 2
“Continuous drug delivery represents a revolutionary shift in ophthalmology, particularly in the treatment of chronic diseases like DME [59].”
Manufacturing consideration, scale-up, and validation in sterile ophthalmic formulation
Üner, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00020-4 · Cited by 2
Liu, X., Wang, Y., Huang, J., Chen, L., Cai, T., Wang, Q., Li, S., Yu, G., Chen, Y., Luo, D., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102578 · Cited by 2
“While preliminary investigations have demonstrated the potential of tFNAs in ocular drug delivery [22 – 24], their application in posterior segment diseases, especially those involving CNV such as wAMD, remains at an early stage and warrants further systematic exploration [25].”
Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.24 · Cited by 2
“41,42 In the present study, we found that daily topical administration of GalNAc-modified siHOTAIR was equally as effective as weekly intravitreal injections, suggesting that topical GalNAc-modified siHOTAIR could be a viable treatment for HOTAIR-associated dysfunction in DR. GalNAc-modified…”
Nagashree, D., Lavanya Akashi, C., N, K. M. B., & Naveen, N. R. (2026) · Current Ophthalmology Reports · doi:10.1007/s40135-025-00345-6 · Cited by 2
Drug delivery across the blood-retinal barrier: Biological gateways for posterior segment therapy
Kim, J., Han, Y. E., Kim, M., Choe, J., Lee, J.-Y., Yang, H., Han, Y., Oh, S. J., Jung, W., Cho, J., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101496 · Cited by 2
Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review
Jain, R., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.56796 · Cited by 3
“Intravitreal injections offer several advantages, including high drug bioavailability, precise dosing, and reduced systemic side effects compared to oral or systemic administration [4].”
BackgroundIntraocular Inflammation Associated with Intravitreal Drug Injections: Current State of the Problem
Валерьевич, Б. Е., Morozova, O. V., Krokhalev, V. Y., & Варежкина, Е. С. (2024) · Офтальмология Восточная Европа · doi:10.34883/pi.2024.14.1.025 · Cited by 2
Piroozmand, S., Soheili, Z., Latifi‐Navid, H., Samiei, S., Kanavi, M. R., Behrooz, A. B., & Hosseinkhani, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141916 · Cited by 2
Sacco, M. A., Aquila, V. R., Gualtieri, S., Verrina, M. C., Tarda, L., Tarallo, A. P., Carbone, A., Ranno, F., Ricci, P., & Aquila, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072996 · Cited by 2
Ocular Pharmacokinetic Studies: Challenges and Best Practices
Bacellar‐Galdino, M., Jain, S. K., & Kaja, S. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1011599 · Cited by 2
WILSON, C. G. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165603-00001 · Cited by 3
Inflammation in the Pathogenesis of Progressive Retinal Dystrophies
Hollingsworth, T. (2021) · Journal of Ophthalmic Research and Vision Care · doi:10.54289/jorvc2100103 · Cited by 3
Бахрушина, Е. О., Pyzhov, V. S., Sakharova, P. S., Демина, Н. Б., Chizhova, D. A., Tabanskaya, T. V., & Lutfullin, M. F. (2023) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2023-530 · Cited by 2
Tools and Data Towards Supporting Quantitative Systems Pharmacology of the Eye – An OverviewPreprint
Kuepfer, L., Fuellen, G., & Stahnke, T. (2022) · Preprints.org · doi:10.20944/preprints202203.0164.v1 · Cited by 2
Efficacy of Ganciclovir in Cytomegalovirus Retinitis via Intravitreal Route in AIDS Patients
Naz, U., Naz, S., Fahad, H. M., & Rizvi, S. F. (2022) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2022.12.1597 · Cited by 1
Miniature Swine Use in Toxicology Studies
Jensen, M. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_125 · Cited by 1
Liu, P., Dong, L., Cai, T., Liu, K., Gao, X., Sun, W. A., Li, A., & Song, X. (2024) · Polymer Science Series A · doi:10.1134/s0965545x24601047 · Cited by 2
Okur, N. Ü., Okur, M. E., Bülbül, E. Ö., Miliotou, Α. N., Karantas, I. D., & Siafaka, P. I. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128373593250619074556 · Cited by 1
Analyzing Photoreceptor Degeneration and Preservation in a Retinitis Pigmentosa Murine Model
de Jesus, M. C. D. S., Cruz, D. P., León, G. S. B., Crisóstomo, M. C., Magalhães, C. F., de Mattos, A. E. R., & Madeira, L. F. (2025) · Journal of Visualized Experiments · doi:10.3791/68324 · Cited by 1
Kanugo, A., & Teli, N. (2025) · Current Drug Delivery · doi:10.2174/0115672018383855251007175252 · Cited by 2
Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration
Nguyen, V. P., Jeong, J., Zhe, J., Zheng, M., Lee, J., Tran, K. A., Wei, Z., Lee, C. H., & Paulus, Y. M. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01783 · Cited by 1
Gene Therapy Advancements in Age-Related Macular Degeneration Treatment
Amaxilati, E., Chatzimichail, E., Tsiropoulos, G. N., Motta, L., Empeslidis, T., Gatzioufas, Z., & Panos, G. D. (2026) · Cells · doi:10.3390/cells15040376 · Cited by 1
Quadrant-Specific Pain in Intravitreal Injection: A Systematic Review and Meta-analysis
Sabaner, M. C., Gunes, I., Divarcı, A., Anguita, R., van Dijk, E. H. C., Desideri, L. F., Cehofski, L. J., & Subhi, Y. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01342-z · Cited by 1
“Potential mechanisms include quadrant-specific differences in conjunctival manipulation, eyelid and speculum traction, local ocular surface sensitivity, and the practical ease of needle entry (e.g., temporal access versus nasal crowding) [5, 6].”
Zhu, M., & Yu, W. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1817987 · Cited by 1
“To overcome the burden of frequent injections and enhance patient compliance, advanced delivery platforms such as sustained-release intravitreal implants, nanoparticle hydrogels, viral vectors, and exosome-based vehicles are being actively explored (Kim and Woo, 2021; Bairagi et al., 2025).”
Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics
Vasudevan, A., Sivanantham, A., Sreekumar, A. B. S., Dayita, M. J., Logeshwaran, N., Suresh, S. S., Padmakumar, S., Madhavan, A., Babu, P., Nair, B. G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167442 · Cited by 1
“…requires a shift toward more advanced analytical tools, such as AI-based research, to predict resistance patterns and guide the development of innovative, anti-biofilm therapies like bacteriophages or enzyme-based EPS degraders that can penetrate the deeper layers of the ocular stroma [64,70].”
A newly anticipated role for Laptm4b in retinal outer segment development
Rodriguez, B., Vázquez, M., & Cai, L. (2022) · Eye · doi:10.1038/s41433-022-01996-6 · Cited by 1
Improved intravitreal injection procedure in mice with electroretinographic evaluation of results
Romanov, I. S., Rotov, A. Y., Astakhova, L. A., & Firsov, M. L. (2022) · Integrative Physiology · doi:10.33910/2687-1270-2022-3-2-233-245 · Cited by 1
Nanotechnology in the diagnosis of ocular diseases, drug delivery, and therapy
Mishra, L., Talegaonkar, S., Rai, M. K., Occhiutto, M. L., & Mishra, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15264-1.00017-8 · Cited by 4
Jian, H., Wang, T., & Pujara, C. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13466-1.00015-5 · Cited by 1
Ocular Novel Drug Delivery Systems
Khazaeli, P., Tabatabaei, M. S., Sayed‐Tabatabaei, L., & Estabragh, M. A. R. (2024) · Wiley eBooks · doi:10.1002/9781119852476.ch11 · Cited by 1
鈴木, 淳. (2012) · 書物・出版と社会変容
An Update on Suprachoroidal Corticosteroid Injections in the Management of Macular Edema
Ismail, O. M., & Henry, C. R. (2022) · Current Ophthalmology Reports · doi:10.1007/s40135-022-00291-7
Treatments for diabetic retinopathy and diabetic macular edema in pipeline
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00011-1
Miniature Swine Use in Toxicology Studies
Jensen, M. L. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_125-1
Abiyoga, K., Primitasari, Y., & Lutfi, D. (2023) · Bali Medical Journal · doi:10.15562/bmj.v12i2.4339
Ottonelli, I. (2023) · theses.fr (ABES) · doi:10.70675/be050293z69a3z4fdfz93c8z9042ae710cac
Stem cell cultures and injections for nerve damage
Bu, A., & Dromel, P. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19085-8.00006-0
Luthfiyah, S., Triwiyanto, T., & Ismath, M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s520409
Progress in Treatment of Macular Edema Secondary to Retinal Vein Occlusion
李, 超. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541321
Cyclic nucleotide signaling as a drug target in retinitis pigmentosa
Vainionpää, K., Montaser, A. B., & Leinonen, H. (2025) · FEBS Letters · doi:10.1002/1873-3468.70107
“Innovative device-assisted and nanotechnology-based approaches aim to overcome the off-target toxicity limitations associated with systemic delivery [112].”
Zardo, H., Ferraz, H. G., Issa, M. G., & Fante, A. S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5348194
Pharmacokinetics and Pharmacogenetics - Principles, Applications, and Challenges
Samardžić, J. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1008053
Narwal, S., Dushyant, Singh, G., Grewal, N., Chanalia, V., & Dhingra, A. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002384586250731104453
Zahir‐Jouzdani, F., Ashrafi, S., Ghaemmaghamian, Z., Kharazian, B., Shahbaz, S., Dinarvand, R., & Atyabi, F. (2025) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-025-00576-9
“It is worth mentioning that, various methods are available to produce microsuspensions, including the precipitation method, high-pressure homogenization (HPH), and media milling (wet ball milling) [37, 38 ].”
Xu, K., & Zhang, X. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03747-4
Tomazoni, E., Penha, F. M., & Rodrigues, E. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_18-1
Karachrysafi, S., Karakousis, V. A., Liatsos, A. C., Kavvadas, D., Ioannou, D., Anastasiadou, P. A., Kofidou, E., Karampatakis, V. E., Sioga, A., Raikos, Ν., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010129
Microneedles in ophthalmology: minimally invasive alternative to traditional methods. Review
Hmaidi, E., Sementsov, K. O., Zernov, I. A., Dikinov, A. Z., Garaeva, D. A., Kholkina, K. A., Tikhanovich, E. D., Lovushkina, A. A., Gumerova, E. R., Lilikov, K. A., et al. (2025) · Ophthalmology Reports · doi:10.17816/ov677111
Intravitreal injection delivered volume under different environmental and training conditions
dos Santos, M. L., Santos, L., Cardoso, A. L., Agra, L. L. D. M., Coelho, J. A. P. D. M., & Melo, G. B. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-07005-2
Critical process parameters in the manufacturing of triamcinolone acetonide intraocular suspension
Zardo, H. (2025) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2025.tde-13112025-183236
VOLPI, D. (2022) · Electronic Theses and Dissertations Repository (University of Pisa)
Ultrasound-Enhanced Retinal Delivery of Engineered Viral Vectors
Link, S. S., Fan, K., Adame, J., Keehn, C. C., Shen, G., Frankfort, B. J., & Szablowski, J. (2026) · Investigative Ophthalmology & Visual Science · doi:10.64898/2026.01.04.697446
Nanotherapeutic potential in glaucoma associated ocular cancers
Lambuk, L., Sadikan, M. Z., Lazaldin, M. A. M., Lambuk, F., Kadir, R., Ismail, N., & Mohamud, R. (2026) · Discover Oncology · doi:10.1007/s12672-025-04169-5
“Promising delivery systems include biodegradable PLGA nanoparticles and lipid-based carriers, which enable sustained siRNA release to posterior ocular tissues [140].”
Afrose, N., Chakraborty, R., Basu, B., Goswami, R., Singh, S., & Prajapati, B. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00536-4
Special Issue: Molecular Mechanisms and Treatment of Retinal Diseases
Lee, D., & Vitiello, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031376
Assessing eIF4E-S209 Signaling and Translationally Regulated Mechanisms in Neurodegeneration
Tuccitto, M. A. (2023) · TSpace (University of Toronto)
Basics of Intraocular Pharmacotherapy
Melo, G. B., & Badaró, E. (2026) · Springer eBooks · doi:10.1007/978-3-031-29358-0_17-1
Reig-López, J., Cuquerella-Gilabert, M., Zarzoso-Foj, J., Mangas‐Sanjuan, V., Merino, V., & Merino‐Sanjuán, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040445
“…delivery systems of biologic drugs into the eye do exist (e.g., biodegradable polymers and implants, reservoir systems and gels, microspheres, devices and non-erodible implants) and good reviews discussing their advantages, drawbacks and current development status can be found elsewhere [16,17,29].”
Harding, P. A., Westbay, J. H., Fletcher, E. R. A., Fan, X., & Fedorchak, M. V. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346473
“There is a need to explore novel methods for ocular drug delivery that address the challenges presented by the ocular anatomy and physiological barriers, limiting drug bioavailability and therapeutic efficacy [1–4].”
"Optimisation of electrical stimulation in the retina of retinitis pigmentosa mouse model rd10"
Nruthyathi (2025) · RWTH Publications (RWTH Aachen) · doi:10.18154/rwth-2026-02802
Shi, J., & Zhang, L. (2026) · International Ophthalmology · doi:10.1007/s10792-026-04120-9
“Accordingly, successful retinal delivery depends not only on the route of administration, but also on the physicochemical properties of the EV formulation, including size, surface charge, membrane composition, and retention profile [123, 124].”
Advances in nanomedicine for ocular inflammatory diseases
Xiang, D., Feng, X., & Zhang, J. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102965 · Cited by 1
Gold Nanoparticle Shape Design for Ophthalmic Imaging and Therapy
Abdelazim, E. B., Mohamed, M. A., Hassab, S. M., Ali, N. O., Ibrahim, R., Nagy, N. S., Eissa, R. A., Eissa, N. G., & Elsabahy, M. (2026) · Pharmaceuticals and Nanotech Connect · doi:10.69709/pnc.2026.190092
Serra, R., Français, C., Boulet, J. F., Pinna, A., Philippakis, E., Zambrowski, O., Mathis, T., Kodjikian, L., & Coscas, F. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07319-9
Metadata
- Authors
- Kim, H. M., & Woo, S. J.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Woo, Se Joon
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 13
- Issue
- 1
- Pages
- 108
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7830424
- OpenAlex
- W3118619250
- Cited by
- 198
- References
- 200
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 35 · 2023: 44 · 2022: 33 · 2021: 18
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation (2020R1F1A1072795, 2018M3A9B5021319)
- National Research Foundation of Korea (2020R1F1A1072795, 2018M3A9B5021319)
- Ministry of Science and ICT, South Korea (2020R1F1A1072795)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- ocular drug delivery, retinal drug delivery, intravitreal injection, intravitreal implant, nanoparticles, hydrogels, port delivery system, anti-VEGF therapy, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular disease, subconjunctival administration, ocular bioavailability, minimally invasive drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.